1721-P: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZT006 Tablet, an Oral GLP-1 Receptor Agonist Peptide, in Healthy Participants, Participants with Overweight or Obesity: A Phase 1 Study
Diabetes · 05.06.2026 · 75 (Supplement_1)
DOI: 10.2337/db26-1721-p ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von WEI HU und 11 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction and Objective: This study was to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of ZT006 tablet, an oral GLP-1 receptor agonist peptide, in healthy participants or participants with overweight/obesity.
Methods
It was a randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD), phase 1 study. In SAD, healthy participants or with overweight (BMI ≥19.0 kg/m2 to ≤28.0 kg/m2) were randomized (3:1 or 4:1) to receive a single dose of ZT006 tablet (5, 10, 20, 40 or 60 mg) or placebo. In MAD cohort 1 and 2, healthy or participants with overweight were randomized (3:1) to receive ZT006 tablet (5/10/20 mg or 5/10/20/40 mg) or placebo, and in cohort 3, participants with overweight or obesity (BMI ≥24.0 kg/m2 to ≤35.0 kg/m2) were randomized (4:1) to receive ZT006 tablets (10/20/40 mg) or placebo. In MAD, ZT006 tablets and placebo were given once daily for 42 days. The primary endpoints were adverse events (AEs) and serious adverse events (SAEs).
Results
In total 42 and 52 participants were enrolled in SAD and MAD, respectively. Most AEs were mild or moderate in severity. Only 1 (1.9%) SAE was reported, which was in MAD cohort 2 and unrelated to ZT006. No treatment-related AEs led to treatment discontinuation. The most common AEs were gastrointestinal which were all mild or moderate. Exposures of ZT006 in SAD and MAD were dose-proportional, with an elimination half-life of approximately 8 days. In MAD, the mean weight loss on Day 43 in ZT006 groups was dose-dependent, and up to 11.7% in cohort 3 which was significantly greater than 4.8% in matched placebo group (p=0.0002). No plateau was observed in MAD.
Conclusion
ZT006 tablet demonstrated a favorable safety and tolerability profile with clinically meaningful weight loss in healthy participants or participants with overweight/obese in 6 weeks. Results support further clinical development of ZT006 tablet for metabolic diseases. Disclosure W. Hu: None. Y. Du: None. Q. Zhang: None. Q. Zhang: None. L. Zheng: None. R. Zhao: None. P. Liu: None. Y. Zu: None. Y. Guo: None. S. Lin: None. X. Zhang: None. Y. Zhang: None.
Zitieren
APA
HU, W., DU, Y., ZHANG, Q., ZHANG, Q., ZHENG, L., ZHAO, R., LIU, P., ZU, Y., GUO, Y., LIN, S., ZHANG, X., & ZHANG, Y. (2026). 1721-P: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZT006 Tablet, an Oral GLP-1 Receptor Agonist Peptide, in Healthy Participants, Participants with Overweight or Obesity: A Phase 1 Study. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-1721-p
Vancouver
HU W, DU Y, ZHANG Q, ZHANG Q, ZHENG L, ZHAO R, et al. 1721-P: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZT006 Tablet, an Oral GLP-1 Receptor Agonist Peptide, in Healthy Participants, Participants with Overweight or Obesity: A Phase 1 Study. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-1721-p
BibTeX
@article{HU2026,
author = {HU, WEI and DU, YIJUN and ZHANG, QIAN and ZHANG, QIN and ZHENG, LIANG and ZHAO, RUIHUA and LIU, PEI and ZU, YUAN and GUO, YUMEI and LIN, SIMEI and ZHANG, XUJIA and ZHANG, YUANYUAN},
title = {1721-P: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZT006 Tablet, an Oral GLP-1 Receptor Agonist Peptide, in Healthy Participants, Participants with Overweight or Obesity: A Phase 1 Study},
journal = {Diabetes},
year = {2026},
volume = {75},
number = {Supplement_1},
doi = {10.2337/db26-1721-p}
}
EUVIMED